• Bristol Myers Squibb won FDA accelerated approval for ZENBEXUS (iberdomide) with daratumumab and dexamethasone in multiple myeloma.
• Cleared for adults with at least one prior line including a proteasome inhibitor and an immunomodulatory agent.
• Decision based on MRD-negative complete response; continued approval hinges on confirmatory progression-free survival results in an ongoing cohort.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20260924614211) on September 25, 2026, and is solely responsible for the information contained therein.